Retevmo (Selpercatinib) Achieves Positive Results in Phase III Clinical Trial
August 5, 2023 – Eli Lilly and Company (Eli Lilly) announced that its RET inhibitor Retevmo (Selpercatinib) has achieved positive top-line data in a Phase III clinical trial for the treatment of patients with RET fusion-positive non-small cell lung cancer (NSCLC).
Trial Results
According to a scheduled interim efficacy analysis conducted by the Independent Data Monitoring Committee (IDMC), patients in the Retevmo arm demonstrated statistically and clinically significant improvements in progression-free survival (PFS) compared to patients receiving standard first-line therapy.
Significance And Outlook
This result suggests that Retevmo Selpercatinib is expected to become a standard first-line therapy for adult patients with newly diagnosed advanced or metastatic RET fusion-positive NSCLC.
Globally, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases, making this advancement important for improving patient prognosis.
Mechanism Of Action And Innovation Of Retevmo
Is a highly selective RET (Rearranged during Transfection) kinase inhibitor, which can precisely inhibit the aberrant signaling pathway caused by RET gene fusion or mutation, and thus inhibit tumor growth and proliferation.
Unlike conventional chemotherapy and broad-spectrum targeted agents, Retevmo is specifically targeted at RET-driven cancers, offering higher efficacy and lower side effects.
Indications and Target Patient Population
Retevmo® is approved for the following indications:
Non-Small Cell Lung Cancer (NSCLC): for patients with advanced or metastatic NSCLC carrying a RET gene fusion.
Thyroid Cancer:
For patients with advanced or metastatic medullary thyroid cancer (MTC) harboring a RET gene fusion.
For patients with advanced or metastatic thyroid cancer carrying RET gene mutations.
Other solid tumors: for patients with advanced or metastatic solid tumors carrying RET gene variants.
Patient Benefits
For patients with RET-driven cancers, the launch of Selpercatinib means new hope.
One NSCLC patient treated with Retevmo shared, “After traditional treatments failed, Retevmo allowed my tumor to shrink significantly with minimal side effects. I can finally reprogram my life.”
Future Outlook
With the widespread use of Retevmo, more patients with RET-driven cancers are expected to benefit from it.
In the future, researchers will further explore the potential of Retevmo® in early-stage cancer treatment and conduct more studies on combination therapies, with the aim of providing patients with more comprehensive treatment options.
About Retevmo
It is developed and manufactured by Eli Lilly and Company and is currently approved in the U.S., Europe and other countries.
For more information, please visit the official Eli Lilly and Company website or consult a healthcare professional.
However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.
We welcome you to reach out to us to get Selpercatinib price. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.
Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.
Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
